{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:26:14Z","timestamp":1789579574469,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001027","name":"Department of Health and Ageing, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,10]]},"abstract":"Summary<\/jats:title>Paritaprevir\/ritonavir\/ombitasvir and dasabuvir with or without ribavirin for 12\u00a0weeks are approved for treatment of chronic HCV<\/jats:styled-content> genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir\/ritonavir\/ombitasvir and dasabuvir with or without ribavirin for 8\u00a0weeks among people with recent HCV<\/jats:styled-content> infection. In this open\u2010label single\u2010arm trial conducted in Australia, England and New Zealand, adults with recent HCV<\/jats:styled-content> (duration of infection <12\u00a0months) received paritaprevir\/ritonavir\/ombitasvir and dasabuvir (with weight\u2010based ribavirin for genotypes 1a and 1, no subtype) for 8\u00a0weeks. The primary endpoint was sustained virological response at 12\u00a0weeks post\u2010treatment (SVR<\/jats:styled-content>12) in the intention\u2010to\u2010treat (ITT<\/jats:styled-content>) population. Thirty people (median age 38\u00a0years, male 93%) commenced treatment (with ribavirin, 97%), of whom 77% (n\u00a0=\u00a023) were HIV<\/jats:styled-content>\u2010positive, 93% (n\u00a0=\u00a028) had genotype 1a infection and 53% (n\u00a0=\u00a016) had ever injected drugs. Median maximum ALT<\/jats:styled-content> in the preceding 12\u00a0months was 433 IU<\/jats:styled-content>\/L (IQR<\/jats:styled-content> 321, 1012). Acute clinical hepatitis with ALT<\/jats:styled-content>\u00a0>\u00a010\u00a0x\u00a0ULN<\/jats:styled-content> was documented in 83% (n\u00a0=\u00a025); one participant (3%) had jaundice. At baseline, median estimated duration of infection was 30 weeks (range 11, 51), and median HCV RNA<\/jats:styled-content> was 5.7 log10<\/jats:sub> IU<\/jats:styled-content>\/mL<\/jats:styled-content> (range 2.7, 7.3). SVR<\/jats:styled-content>12 was achieved in 97% (29\/30; early discontinuation at week 2, n\u00a0=\u00a01; per protocol 100%, 29\/29). No relapse or reinfection was observed. In conclusion, paritaprevir\/ritonavir\/ombitasvir and dasabuvir (with ribavirin) for eight weeks were highly effective among HIV<\/jats:styled-content>\u2010positive and HIV<\/jats:styled-content>\u2010negative individuals with recent HCV<\/jats:styled-content> infection. These data support the use of this shortened duration direct\u2010acting antiviral regimen in this population.<\/jats:p>","DOI":"10.1111\/jvh.12917","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T16:16:02Z","timestamp":1523895362000},"page":"1180-1188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV<\/scp> genotype 1 infection"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"M.","family":"Martinello","sequence":"first","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"},{"name":"Department of Infectious Diseases and Immunology St Vincent's Hospital Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\/HIV Medicine Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gane","sequence":"additional","affiliation":[{"name":"New Zealand Liver Transplant Unit Auckland City Hospital Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Orkin","sequence":"additional","affiliation":[{"name":"Barts Health Royal London Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Imperial College NHS Trust St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"},{"name":"Department of Infectious Diseases and Immunology St Vincent's Hospital Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Petoumenos","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. L.","family":"Applegate","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tu","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marks","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pagani","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grebely","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program Kirby Institute UNSW Sydney Sydney NSW Australia"},{"name":"Department of Infectious Diseases and Immunology St Vincent's Hospital Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"WHO.Global Hepatitis Report 2017.Geneva:WHO;2017. Report No.: CC BY\u2010NC\u2010SA 3.0 IGO."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000834"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.60"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_7_9_1","unstructured":"AASLD\u2010IDSA.Recommendations for testing managing and treating hepatitis C2016[Available from:http:\/\/www.hcvguidelines.org\/. Accessed 1 Dec 2017."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.07.003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28228"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30408-X"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.07.005"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV\u2010infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","author":"European Aids Treatment Network Acute Hepatitis C. Infection Consensus Panel","year":"2011","journal-title":"AIDS"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.019"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw075"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000179"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29611"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30003-1"},{"issue":"1","key":"e_1_2_7_21_1","first-page":"113A","article-title":"100% SVR with 8\u00a0weeks of ledipasvir\/sofosbuvir in HIV\u2010infected Men with Acute HCV Infection: results from the SWIFT\u2010C Trial","volume":"66","author":"Naggie S","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28844"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.022"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.97"},{"key":"e_1_2_7_26_1","unstructured":"WHO.Global health sector strategy on viral hepatitis 2016\u20132021.Geneva Switzerland:WHO;2016June 2016. Contract No.: WHO\/HIV\/2016.06."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30075-9"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T06:44:20Z","timestamp":1695019460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/jvh.12917"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12917","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"2018-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}